// App-Quantinova.ai

105 : A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Tong Shen

  • Susan Halabi

  • Daniel J. George

  • Gabor Kemeny

  • Rhonda Lynn Bitting

  • Patricia Kartcheske

  • Elizabeth Embree

  • Karla Morris

  • Carolyn Winters

  • Tracy Jaffe

  • Mark T. Fleming

Medical Centers

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Duke Cancer Institute, Durham, NC

  • Virginia Oncology Associates, Norfolk, VA

  • Duke University Medical Center, Durham, NC

  • Duke University, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Temsirolimus

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT00887640

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved